Search clinical trials for: HM201

Total 23 results

InnoBM Pharmaceuticals Co., Ltd.

Recruiting

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors (BM201-1001)

Advanced Solid Tumors

China
Novartis Pharmaceuticals

Terminated

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Uveal Melanoma

United States, Australia, France, Netherlands, Spain, Norway
Novartis Pharmaceuticals

Terminated

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Allogeneic Stem Cell Transplantation

Italy, Germany, Spain
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Liposarcoma

France, Taiwan, Germany, Spain, Canada, Singapore
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Advanced Solid and Hematological TP53wt Tumors

France, Netherlands, Spain, Germany, Singapore, Japan, Taiwan, United States
Kitasato University
Aetas Pharma Co. Ltd.

Unknown

First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

Japan
Centre Leon Berard
Novartis; National Cancer Institute, France

Recruiting

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC)

Advanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma

France
Yuji KUMAGAI
Aetas Pharma Co. Ltd.

Completed

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan
Kitasato University
Aetas Pharma Co. Ltd.

Completed

Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan
Vical

Completed

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Genital Herpes Simplex Type 2

United States
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Prestige Biopharma Limited

Completed

A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects (TROIKA-1)

Healthy Volunteers

Australia
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
Assembly Biosciences

Terminated

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

United States, Canada
Centre Leon Berard
Novartis

Completed

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)

Colorectal Cancer | Metastatic Cancer | Advanced Cancer

France
Syneos Health
Himuka AM Pharma Corp.

Recruiting

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

Crohn's Disease | Ulcerative Colitis

Australia
University Hospital Inselspital, Berne

Terminated

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. (HDMM)

AML, Adult

Switzerland
Novartis Pharmaceuticals

Active, not recruiting

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Acute Myeloid Leukemia

Italy, Hong Kong, Israel, Hungary, Turkey, Malaysia, United States
Centre Leon Berard

Recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)

Malignant Solid Tumor

France
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

United States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
Prestige Biopharma Limited

Completed

A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients (TROIKA)

HER2 Positive Breast Cancer

Spain, Malaysia, Estonia, Hungary, Thailand, Belarus, Bulgaria, France, Georgia, Italy, Poland, Russian Federation, Ukraine
Novartis Pharmaceuticals

Withdrawn

HDM201 Added to CT in R/R or Newly Diagnosed AML

Leukemia, Myeloid, Acute

Search clinical trials for: HM201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations